{"id":"insulin-empaglifozin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Volume depletion"},{"rate":null,"effect":"Diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin acts as an exogenous hormone replacement to facilitate glucose uptake into cells and suppress hepatic glucose production. Empaglifozin, an SGLT2 inhibitor, blocks reabsorption of filtered glucose in the proximal tubule, allowing excess glucose to be excreted in urine. Together, they provide dual mechanisms for glycemic control in type 2 diabetes.","oneSentence":"This combination uses insulin to lower blood glucose while empaglifozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:07.539Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Insulin/Empaglifozin","genericName":"Insulin/Empaglifozin","companyName":"University of Campania Luigi Vanvitelli","companyId":"university-of-campania-luigi-vanvitelli","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses insulin to lower blood glucose while empaglifozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}